Evidence map›Paper›PMID 26526532›Full record

ArticleNature reviews. Neurology2015

Neurodegenerative disease: C9orf72 repeats compromise nucleocytoplasmic transport.

Marka van Blitterswijk, Rosa Rademakers

Abstract readComment
PubMed Publisher
In one paragraph

Article in Nature reviews. Neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Molecular Genetics of Neurodegenerative Dementias.Cold Spring Harbor perspectives in biology · 2017
    Review
  7. Mouse Models ofFrontiers in cellular neuroscience · 2017
    Review
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Marka van BlitterswijkDepartment of Neuroscience, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
Rosa RademakersDepartment of Neuroscience, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA.

Funding

THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI BU, GUOJUN · 1999 to 2018
$36.9M
Uncovering new genes and disease modifiers for ALS and related disordersU54NS092091 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Michael Benatar · 2014 to 2026
$19.8M
Project 3: Neuropathology of the multi-proteinopathy of c9FTD/ALS.P01NS084974 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2014 to 2024
$17.6M
GGGGCC hexanucleotide repeat expansions in neurodegenerative diseaseR01NS080882 · NINDS · MAYO CLINIC JACKSONVILLE · PI RADEMAKERS, ROSA · 2012 to 2016
$1.6M
Molecular genetic studies of progranulin regulators in FTLD and ALSR01NS076471 · NINDS · MAYO CLINIC JACKSONVILLE · PI RADEMAKERS, ROSA · 2013 to 2016
$1.4M
NIA NIH HHS P50 AG016574NINDS NIH HHS P01 NS084974NINDS NIH HHS R01 NS076471NINDS NIH HHS R01 NS080882NINDS NIH HHS U54 NS092091
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Active Transport, Cell NucleusAmyotrophic Lateral SclerosisAnimalsCell NucleusDipeptidesDNA Repeat ExpansionDrosophila melanogasterFemaleFrontotemporal DementiaHumansMaleOpen Reading FramesProteinsRNA TransportDipeptidesProteins

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.